Nexalin Technology (NASDAQ:NXL – Get Free Report) and LogicMark (OTCMKTS:LGMKD – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, dividends, risk, profitability and institutional ownership.
Analyst Recommendations
This is a breakdown of recent ratings for Nexalin Technology and LogicMark, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nexalin Technology | 1 | 0 | 0 | 0 | 1.00 |
| LogicMark | 0 | 1 | 0 | 0 | 2.00 |
Risk & Volatility
Nexalin Technology has a beta of 3.95, suggesting that its share price is 295% more volatile than the S&P 500. Comparatively, LogicMark has a beta of 1.67, suggesting that its share price is 67% more volatile than the S&P 500.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nexalin Technology | $300,000.00 | 11.02 | -$8.22 million | ($14.41) | -0.31 |
| LogicMark | $9.90 million | 0.11 | -$9.00 million | ($94.52) | -0.01 |
Nexalin Technology has higher earnings, but lower revenue than LogicMark. Nexalin Technology is trading at a lower price-to-earnings ratio than LogicMark, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Nexalin Technology and LogicMark’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nexalin Technology | -4,141.94% | -278.24% | -218.42% |
| LogicMark | -90.21% | -57.08% | -44.90% |
Institutional & Insider Ownership
0.7% of Nexalin Technology shares are held by institutional investors. Comparatively, 7.9% of LogicMark shares are held by institutional investors. 16.9% of Nexalin Technology shares are held by company insiders. Comparatively, 2.2% of LogicMark shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
LogicMark beats Nexalin Technology on 7 of the 12 factors compared between the two stocks.
About Nexalin Technology
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.
About LogicMark
LogicMark, Inc. provides personal emergency response systems (PERS), health communications devices, and Internet of Things (IoT) technology that creates a connected care platform in the United States. The company’s devices provide people with the ability to receive care at home and age independently and to check, manage, and monitor a loved one’s health and safety remotely. It also manufactures and distributes non-monitored and monitored personal emergency response systems, which are offered through the United States Veterans Health Administration (VHA), direct-to-consumers, healthcare durable medical equipment dealers and distributors, monitored security dealers and distributors, and its ecommerce website logicmark.com and Amazon.com. The company was formerly known as Nxt-ID, Inc. and changed its name to LogicMark, Inc. in March 2022. LogicMark, Inc. was founded in 2006 and is based in Louisville, Kentucky.
Receive News & Ratings for Nexalin Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexalin Technology and related companies with MarketBeat.com's FREE daily email newsletter.
